| 143.22 3.99 (2.87%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 174.59 | 1-year : | 203.92 |
| Resists | First : | 149.47 | Second : | 174.59 |
| Pivot price | 126.41 |
|||
| Supports | First : | 126.62 | Second : | 112.5 |
| MAs | MA(5) : | 135.93 |
MA(20) : | 124.28 |
| MA(100) : | 125.68 |
MA(250) : | 139.99  |
|
| MACD | MACD : | 4.1 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 75 |
D(3) : | 79.3 |
| RSI | RSI(14): 75.9 |
|||
| 52-week | High : | 196.25 | Low : | 107 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ICUI ] has closed above the upper band by 3.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 92.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 144.44 - 145.01 | 145.01 - 145.51 |
| Low: | 137.38 - 138.08 | 138.08 - 138.68 |
| Close: | 142 - 143.15 | 143.15 - 144.15 |
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
Sun, 09 Nov 2025
ICU Medical, Inc. (NASDAQ:ICUI) Q3 2025 Earnings Call Transcript - Insider Monkey
Fri, 07 Nov 2025
ICUI Q3 Deep Dive: Strategic Execution Drives Margin Gains Amid Revenue Headwinds - The Globe and Mail
Fri, 07 Nov 2025
ICU Medical (ICUI) Shares Skyrocket, What You Need To Know - The Globe and Mail
Fri, 07 Nov 2025
ICU Medical Inc reports results for the quarter ended September 30 - Earnings Summary - TradingView
Fri, 07 Nov 2025
ICU Medical Inc (ICUI) Q3 2025 Earnings Call Highlights: Strong EPS Growth Amid Revenue Challenges - Yahoo Finance
Thu, 06 Nov 2025
ICU Medical (ICUI) Surpasses Q3 Earnings and Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 25 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 2.8 (%) |
| Held by Institutions | 112.8 (%) |
| Shares Short | 1,280 (K) |
| Shares Short P.Month | 1,450 (K) |
| EPS | -1.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 85.7 |
| Profit Margin | -1.6 % |
| Operating Margin | 4.8 % |
| Return on Assets (ttm) | 1.8 % |
| Return on Equity (ttm) | -1.8 % |
| Qtrly Rev. Growth | -8 % |
| Gross Profit (p.s.) | 34.43 |
| Sales Per Share | 95.99 |
| EBITDA (p.s.) | 13.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 139 (M) |
| Levered Free Cash Flow | 248 (M) |
| PE Ratio | -94.23 |
| PEG Ratio | 0 |
| Price to Book value | 1.67 |
| Price to Sales | 1.49 |
| Price to Cash Flow | 25.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|